Aurinia Pharmaceuticals vs Evolus
AUPH and EOLS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AUPH and EOLS compare
Aurinia Pharmaceuticals is the larger company, worth 4.4 times as much as Evolus ($2.2B against $490M).
Aurinia Pharmaceuticals grew revenue faster over the last twelve months (21.0% versus 13.9% for Evolus).
Aurinia Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 97.7% compared with −9.6% at Evolus.
Aurinia Pharmaceuticals scores higher on the StockData Score (13 against 7 for Evolus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AUPH | EOLS |
|---|---|---|
| Size and price | ||
| Market cap | $2.2B | $490M |
| Share price | $16.21 | $7.42 |
| Change, 1 year | 8.9% | 5.2% |
| Change, 5 years | −43.1% | 16.3% |
| Beta (5Y) | 1.07 | 1.14 |
| Employees | 128 | 334 |
| StockData Score | ||
| Total score | 13 (better) | 7 |
| Valuation score | 3 (better) | 1 |
| Growth score | 3 | 3 |
| Performance score | 4 (better) | 2 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 7.1× | – |
| P/S | 6.8× | 1.5× (better) |
| P/B | 3.3× | – |
| EV/EBITDA | 12.1× | – |
| FCF yield | – | −1.0% |
| Fair value | $41.25 | – |
| Margin of safety | 60.7% | – |
| Growth | ||
| Revenue growth (TTM) | 21.0% (better) | 13.9% |
| Revenue growth, 5Y average | 41.4% (better) | 39.4% |
| Net income growth (TTM) | 304% | – |
| EPS growth (TTM) | 309% | – |
| Profitability | ||
| Gross margin | 90.6% (better) | 66.4% |
| Operating margin | 48.6% (better) | −4.8% |
| Net margin | 97.7% (better) | −9.6% |
| FCF margin | – | −1.5% |
| Return on equity | 61.4% | – |
| Return on invested capital | 34.6% (better) | −16.3% |
| Financial health | ||
| Interest coverage | 40.4× (better) | −1.0× |
| Current ratio | 6.12 (better) | 1.42 |
| Altman Z-score | 8.55 (better) | −1.28 |
| Piotroski F-score | 8 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | 3.4% | – |
| Shareholder yield | 3.4% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 58.3% | 84.0% |
| Held by insiders | 17.3% | 4.1% |
| Insider net buying, 12 months | $24.6M (better) | −$1.8M |
| Short interest, % of float | 6.4% | 9.5% |
Go deeper
- AUPH stock overview
- AUPH income statement
- AUPH valuation and score
- EOLS stock overview
- EOLS income statement
- EOLS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.